Structures by: May N. V.
Total: 32
Bis(3-hydroxy-1-methyl-4-pyridinecarboxylato)-monoaqua-copper(II) trihydrate
C14H14CuN2O7,3(H2O)
New Journal of Chemistry (2019) 43, 27 10699
a=6.6329(4)Å b=9.5423(6)Å c=13.8849(9)Å
α=85.573(2)° β=89.691(2)° γ=87.100(2)°
"bis(μ2-4-hydroxy-1-(2-hydroxyethyl)-6-methyl-3-pyridinecarboxylato)-bis(μ2-4-hydroxy-1-(2-hydroxyethyl)-6-methyl-3-pyridinecarboxylato)-bis(μ2-4-hydroxy-1-(2-hydroxyethyl)-6-methyl-3-pyridinecarboxylato)-tri-copper(II) nonahydrate'"
C54H60Cu3N6O24,12(H2O),4(HO),2(O)
New Journal of Chemistry (2019) 43, 27 10699
a=12.1956(4)Å b=12.4877(4)Å c=12.6185(5)Å
α=98.9780(10)° β=91.0710(10)° γ=113.1190(10)°
Bis(μ2-4-hydroxy-1-methyl-3-pyridinecarboxylato)-bis(μ2-4-hydroxy-1-methyl-3-pyridinecarboxylato)-di-copper(II) tetrahydrate'
C28H24Cu2N4O12,4(H2O)
New Journal of Chemistry (2019) 43, 27 10699
a=7.9481(4)Å b=8.7896(4)Å c=11.4208(6)Å
α=90.722(3)° β=106.939(3)° γ=104.188(3)°
Bis(μ2-3-hydroxy-1,2,6-trimethyl-4-pyridinecarboxylato)-di-copper(II) hexahydrate'
C36H40Cu2N4O12,6(H2O),6(H1.5O)
New Journal of Chemistry (2019) 43, 27 10699
a=9.4860(4)Å b=11.1725(5)Å c=12.3239(5)Å
α=98.4870(10)° β=102.3390(10)° γ=106.5450(10)°
Catena-(bis(μ2-4-hydroxy-1,6-dimethyl-3-pyridinecarboxylato)-copper(II) trihydrate
C16H16CuN2O6,3(H2O)
New Journal of Chemistry (2019) 43, 27 10699
a=13.5554(8)Å b=12.9227(6)Å c=10.2747(5)Å
α=90° β=90° γ=90°
C18H20ClCuN5OS,CH4O
C18H20ClCuN5OS,CH4O
Journal of medicinal chemistry (2019) 62, 2 512-530
a=16.5043(12)Å b=17.7857(12)Å c=7.1311(6)Å
α=90° β=96.241(3)° γ=90°
C14H21N5OS
C14H21N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=6.1236(4)Å b=7.9500(6)Å c=30.956(2)Å
α=90° β=92.419(4)° γ=90°
3(C16H22ClCuN5O2S),1.75(CH4O)
3(C16H22ClCuN5O2S),1.75(CH4O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=22.2413(7)Å b=8.3324(2)Å c=31.9121(9)Å
α=90° β=90.5654(13)° γ=90°
3(C16H22ClCuN5OS),0.75(CH4O)
3(C16H22ClCuN5OS),0.75(CH4O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=24.702(4)Å b=9.1959(14)Å c=25.064(5)Å
α=90° β=100.971(6)° γ=90°
C12H17N5OS
C12H17N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=11.544(3)Å b=13.204(3)Å c=10.086(3)Å
α=90° β=112.081(7)° γ=90°
C18H21N5OS
C18H21N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=7.1287(2)Å b=15.0536(6)Å c=16.4704(6)Å
α=90° β=97.810(2)° γ=90°
C16H23N5O2S
C16H23N5O2S
Journal of medicinal chemistry (2019) 62, 2 512-530
a=13.3622(18)Å b=5.8899(6)Å c=21.414(3)Å
α=90° β=91.631(5)° γ=90°
C13H18ClCuN5OS
C13H18ClCuN5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=15.7566(11)Å b=14.2967(9)Å c=14.2703(10)Å
α=90° β=92.971(3)° γ=90°
(C12H18ClCuN5O2S),2(H2O)
(C12H18ClCuN5O2S),2(H2O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=9.2626(8)Å b=9.5087(8)Å c=11.0617(9)Å
α=89.565(2)° β=76.519(2)° γ=67.742(2)°
C12H16ClCuN5OS,C3H7NO
C12H16ClCuN5OS,C3H7NO
Journal of medicinal chemistry (2019) 62, 2 512-530
a=9.3959(3)Å b=19.8889(6)Å c=10.9744(3)Å
α=90° β=108.3661(7)° γ=90°
2-(2-fluorophenyl)-1H-benzimidazole
C13H9FN2
CrystEngComm (2020)
a=7.1246(3)Å b=10.0327(4)Å c=29.6291(14)Å
α=90° β=90° γ=90°
2-(2-Bromophenyl)-1H-benzimidazole
C13H9BrN2
CrystEngComm (2020)
a=7.007(3)Å b=9.936(3)Å c=32.745(3)Å
α=90° β=90° γ=90°
Meta-bromo-benzimidazole
C13H9BrN2
CrystEngComm (2020)
a=12.6755(16)Å b=9.6559(18)Å c=9.7645(15)Å
α=90° β=111.638(9)° γ=90°
2-((1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)methylene)hydrazine-1-carbothioamide '
C12H15N3OS
New Journal of Chemistry (2020) 44, 28 12154-12168
a=8.8483(7)Å b=10.5831(7)Å c=13.2516(10)Å
α=90° β=102.518(7)° γ=90°
Chloro-(2-((1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)methylene)hydrazine-1-carbothioamide)-copper(II)
C12H14ClCuN3OS
New Journal of Chemistry (2020) 44, 28 12154-12168
a=12.3620(7)Å b=9.1718(5)Å c=24.3156(13)Å
α=90° β=90° γ=90°
Bis(tetrakis(Pyridine)-silver(I)) octakis(bis(pyridine)-silver(i)) decapermanganate
4(C10H10AgMnN2O4),C20H20AgN4,MnO4
RSC Advances (2019) 9, 49 28387
a=21.982(3)Å b=21.982(3)Å c=7.5974(2)Å
α=90° β=90° γ=90°
2-(3-Chlorophenyl)-1H-benzimidazole
C13H9ClN2
CrystEngComm (2020)
a=12.5894(10)Å b=9.5051(8)Å c=9.7495(7)Å
α=90° β=111.933(8)° γ=90°
7-(piperidin-1-ylmethyl)quinolin-8-ol
C15H18N2O
Dalton transactions (Cambridge, England : 2003) (2018) 47, 47 17032-17045
a=8.9362(7)Å b=11.4735(10)Å c=12.7458(11)Å
α=90° β=90° γ=90°
Bis(7-(morpholin-4-ylmethyl)quinolin-8-ol)-bis-(μ-2-(7-(morpholin-4-ylmethyl)quinolin-8-ol)-di-copper(II) tetrachlorid dimethanol solvate dihydrate
C56H64Cu2N8O8,2(CH4O),Cl4,2(H2O)
Dalton transactions (Cambridge, England : 2003) (2018) 47, 47 17032-17045
a=25.0347(19)Å b=10.5428(7)Å c=23.7514(17)Å
α=90° β=93.299(2)° γ=90°
5-chloro-7-{[(2-fluorobenzyl)amino]methyl}quinolin-8-ol
C17H15ClFN2O,Cl,H2O
Dalton transactions (Cambridge, England : 2003) (2018) 47, 47 17032-17045
a=7.0220(3)Å b=9.4970(5)Å c=13.8230(6)Å
α=95.430(2)° β=101.7900(10)° γ=99.440(2)°
Bis(7-(piperidin-1-ylmethyl)quinolin-8-ol)-copper(II) dichlorid
C30H36CuN4O2,2(Cl)
Dalton transactions (Cambridge, England : 2003) (2018) 47, 47 17032-17045
a=6.5336(2)Å b=10.8906(4)Å c=20.7810(7)Å
α=90° β=91.408(2)° γ=90°
Bis-(5-chloro-7{[(2-fluorobenzyl)amino]methyl}quinolin-8-ol)-aqua-copper(II) zinctetrachlorid methanol solvate
C35H32Cl2CuF2N4O3,Cl4Zn,CH4O
Dalton transactions (Cambridge, England : 2003) (2018) 47, 47 17032-17045
a=11.8498(12)Å b=12.9144(11)Å c=14.7891(17)Å
α=76.700(3)° β=72.214(3)° γ=67.890(3)°
Chloro-(η^5^-pentamethylcyclopentadienyl)-(quinolin-8-olato)- rhodium'
C19H21ClNORh,3(H2O)
Dalton transactions (Cambridge, England : 2003) (2017) 46, 13 4382-4396
a=15.9461(6)Å b=16.3041(6)Å c=7.6492(3)Å
α=90° β=97.1320(10)° γ=90°
C13H19N5OS
C13H19N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=22.7776(4)Å b=6.85850(10)Å c=9.8800(2)Å
α=90° β=98.889(2)° γ=90°
Levomepromazine-maleate
C19H25N2OS,C4H3O4
Acta Crystallographica Section E (2016) 72, 5 612-615
a=11.6395(5)Å b=19.0487(6)Å c=20.4977(7)Å
α=90° β=90° γ=90°
Diethyl-2-acetoxy-2-(3-(4-nitrophenyl)3-oxo-1-phenylpropyl)malonate
C24H25N1O9
Acta Crystallographica Section E (2016) 72, 2 257-260
a=11.0111(7)Å b=13.1762(8)Å c=15.8196(9)Å
α=90° β=93.802(2)° γ=90°
Diethyl 3-(3-chlorophenyl)-2,2-dicyanocyclopropane-1,1-dicarboxylate
C17H15ClN2O4
Acta Crystallographica Section E (2016) 72, 2 253-256
a=8.9221(6)Å b=9.1927(7)Å c=20.3446(16)Å
α=90° β=93.829(2)° γ=90°